GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Soligenix Inc.
Soligenix is a biotech company focused on rare diseases. Its stock price reflects the long and arduous journey to approval of its drugs. The chart is a story of ups and downs due to positive news and clinical trial failures.
Share prices of companies in the market segment - Pharma infections
Soligenix is a biopharmaceutical company developing drugs to treat rare diseases such as cutaneous T-cell lymphoma and childhood mucositis. We've categorized it as a Pharmaceutical: Infections company. The chart below shows how the market values companies working in the orphan disease field.
Broad Market Index - GURU.Markets
Soligenix is a biopharmaceutical company with a diversified development portfolio, including treatments for rare diseases and vaccine development. Its broad focus makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Soligenix compares to it.
Change in the price of a company, segment, and market as a whole per day
SNGX - Daily change in the company's share price Soligenix Inc.
Soligenix, Inc.'s daily stock price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for rare diseases.
Daily change in the price of a set of shares in a market segment - Pharma infections
Soligenix specializes in drugs for rare diseases, which creates a unique volatility profile. The chart below shows the average daily price fluctuations for biotech companies in this category. This provides a benchmark for comparing how SNGX stock performance deviates from the overall sector trend.
Daily change in the price of a broad market stock, index - GURU.Markets
Soligenix is a pharmaceutical company specializing in infectious diseases and rare diseases. Its shares are driven by news about new drug developments. This dynamic, specific to the pharmaceutical industry, creates fluctuations that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Soligenix Inc.
For Soligenix, Inc., year-over-year performance is a reflection of its developments in rare disease treatments. Its 12-month market capitalization is entirely dependent on the FDA's approval of its drug for cutaneous T-cell lymphoma. Approval would be a fundamental breakthrough for the company after years of development and clinical trials.
Annual dynamics of market capitalization of the market segment - Pharma infections
Soligenix, Inc. is a late-stage biopharmaceutical company developing drugs for rare diseases. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Soligenix, with its diversified pipeline from rare diseases to biodefense, represents a complex biotech story. Its performance relative to the market reflects investors' assessment of the likelihood of success on multiple fronts. Progress in any one area could be a powerful catalyst for growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Soligenix Inc.
Soligenix is a late-stage biopharmaceutical company. Its monthly performance is extremely sensitive to regulatory decisions. FDA news regarding its skin and biodefense drugs could cause significant price movements.
Monthly dynamics of market capitalization of the market segment - Pharma infections
Soligenix is a late-stage biotech company developing drugs to treat rare diseases such as cutaneous T-cell lymphoma and childhood mucositis. The chart below illustrates the overall dynamics of the biotech sector, where focusing on orphan diseases is a proven strategy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Soligenix is a biotech company developing drugs for rare diseases and biodefense. Its business depends on successful research and government contracts. Shares can move on non-market news, such as government procurement of biodefense products.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Soligenix Inc.
Soligenix is a biopharmaceutical company focused on rare diseases and biodefense. Its weekly stock price is volatile and depends on the results of clinical trials and government contracts.
Weekly dynamics of market capitalization of the market segment - Pharma infections
Soligenix, Inc. develops treatments for rare diseases. This chart is a tool for assessing how news about clinical trials and drug status impacts stocks in the short term compared to the overall trend in the orphan pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Soligenix, Inc. is a pharmaceutical company whose stock moves to the rhythm of news about clinical trials and drug approvals. The chart clearly shows how its weekly performance is detached from the broader market, moving along its own unique trajectory.
Market capitalization of the company, segment and market as a whole
SNGX - Market capitalization of the company Soligenix Inc.
The Soligenix chart shows the biotech company's long journey. Its market capitalization reflects investor hopes for its developments in treating rare diseases, such as cutaneous T-cell lymphoma, and in vaccines. It's a story of scientific tenacity and funding.
SNGX - Share of the company's market capitalization Soligenix Inc. within the market segment - Pharma infections
Soligenix is a biopharmaceutical company developing treatments for rare diseases, such as cutaneous T-cell lymphoma, and vaccines. Its market capitalization in the infectious diseases and oncology segment reflects its diversified portfolio. The company's market capitalization is a composite assessment of the potential of its various programs.
Market capitalization of the market segment - Pharma infections
Soligenix develops drugs to treat rare diseases. How big is this industry? The chart below shows the overall market capitalization of the infectious disease pharmaceutical sector. Its dynamics reflect how biotech companies are finding significant opportunities in helping small groups of previously neglected patients.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Soligenix chart shows how the market values a biotech company with a diversified portfolio in rare diseases and biodefense. Its market cap reflects the likelihood of success in areas as diverse as skin cancer treatment and vaccine development. It's a diagram that illustrates the complex journey of a small pharmaceutical company.
Book value capitalization of the company, segment and market as a whole
SNGX - Book value capitalization of the company Soligenix Inc.
For Soligenix, a biopharmaceutical company, book value is its tangible asset base, consisting of rights to drug candidates and financial reserves for late-stage clinical trials. The chart below shows how this critical scientific and financial capital has changed.
SNGX - Share of the company's book capitalization Soligenix Inc. within the market segment - Pharma infections
Soligenix, Inc. is a biopharmaceutical company whose tangible assets include laboratories and partner manufacturing facilities for developing vaccines and treatments for rare diseases. The chart shows the percentage of this specialized R&D and manufacturing infrastructure the company controls.
Market segment balance sheet capitalization - Pharma infections
Soligenix is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Soligenix focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Soligenix's assets represent a diversified development portfolio, including treatments for rare diseases such as cutaneous T-cell lymphoma and the development of room-stable vaccines. Its book value reflects the capital available to support these diverse programs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Soligenix Inc.
Soligenix is a biotech company focused on rare diseases and biodefense. Its market capitalization is a valuation of its late-stage development. The chart shows how the market reacts to its interactions with regulators, such as the FDA.
Market to book capitalization ratio in a market segment - Pharma infections
Soligenix is a biopharmaceutical company focused on treating rare diseases and developing vaccines. Its valuation depends on the success of its diversified portfolio. The chart shows how investors value the value of its various programs relative to its current assets.
Market to book capitalization ratio for the market as a whole
Soligenix is a late-stage biopharmaceutical company. Its valuation reflects not only the potential of future products but also the lower risk compared to early-stage companies. This chart helps understand how the maturity of development impacts the market-to-book value ratio in biotech.
Debts of the company, segment and market as a whole
SNGX - Company debts Soligenix Inc.
Soligenix is a biopharmaceutical company developing treatments for rare diseases and biodefense. Working with government contracts and developing for niche markets requires a specific approach to financing. This chart shows how the company raises capital to support its diverse and complex programs, from oncology to vaccines.
Market segment debts - Pharma infections
Soligenix is a late-stage biopharmaceutical company with products for rare diseases. Its financial future depends on regulatory approval. This chart shows the company's cash reserves, which are needed to fund its operations while awaiting regulatory approval.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Soligenix Inc.
Soligenix is a late-stage biopharmaceutical company. This chart shows its financial structure. Even at this late stage, the risk of clinical trial failure or regulatory rejection remains high. Therefore, debt is a significant risk factor that could jeopardize the entire company.
Market segment debt to market segment book capitalization - Pharma infections
Soligenix is a late-stage biopharmaceutical company developing treatments for rare diseases such as cutaneous T-cell lymphoma. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing the company's financial strategy during the final stages of clinical trials and preparation for a potential product launch.
Debt to book value of all companies in the market
Soligenix, Inc. is a biopharmaceutical company focused on rare diseases and biodefense. It is in late-stage development and approaching potential commercialization. This chart helps understand the company's access to debt financing for product launch preparation, compared to more traditional biotech equity financing.
P/E of the company, segment and market as a whole
P/E - Soligenix Inc.
For Soligenix, a biopharmaceutical company focused on rare diseases and biodefense, the P/E ratio is irrelevant. The company lacks consistent profitability. Its valuation is a composite of investors' faith in its diverse pipeline, including potential government contracts.
P/E of the market segment - Pharma infections
Soligenix is a late-stage biopharmaceutical company specializing in the treatment of rare diseases with unmet medical needs, such as cutaneous T-cell lymphoma. This chart shows the average valuation for the sector, providing investors with context for evaluating Soligenix's portfolio.
P/E of the market as a whole
Soligenix is a biopharmaceutical company with a diversified portfolio, including rare disease treatments and vaccine development. Its valuation reflects the combined potential of its programs. It is not tied to the overall economic trends shown in this chart, but rather depends on research data across several areas.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Soligenix Inc.
Soligenix is a late-stage biopharmaceutical company developing drugs for rare diseases such as cutaneous T-cell lymphoma and childhood mucositis. This chart reflects investor expectations for regulatory decisions on its lead candidates. The valuation is highly dependent on upcoming regulatory events.
%20P%2FE%20Soligenix%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Soligenix-Inc.&v=1772513689236 "Chart of the company's future (projected) P/E Soligenix Inc.")
Future (projected) P/E of the market segment - Pharma infections
Soligenix is a late-stage biopharmaceutical company focused on rare diseases and biodefense. Its valuation relative to other biotechs reflects investor sentiment about its drug candidates, demonstrating how the market assesses its chances of obtaining regulatory approval and successful commercialization.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772513689286 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
Soligenix is a late-stage biopharmaceutical company with developments in rare diseases, such as cutaneous T-cell lymphoma, and vaccines. This chart shows the overall investor appetite for risk. For biotechs approaching commercialization, a positive environment is essential to ensure a successful product launch.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513689346 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Soligenix Inc.
Soligenix is a late-stage biopharmaceutical company developing treatments for rare diseases such as cutaneous T-cell lymphoma. The financial results illustrated in this chart depend on the results of clinical trials and potential regulatory approval of its drugs.
Profit of companies in the market segment - Pharma infections
Soligenix is a biopharmaceutical company developing drugs for rare diseases and biodefense. This chart shows the overall profitability of the infectious disease pharmaceutical sector. It helps assess the extent to which government programs and the commercial market support the development of drugs for rare but dangerous threats.
Overall market profit
Soligenix is a biopharmaceutical company developing drugs for rare diseases and biodefense. Its business depends on successful clinical trials and government contracts. These factors are unrelated to general economic cycles, making SNGX unaffected by the dynamics shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Soligenix Inc.
Soligenix is a biopharmaceutical company focused on developing treatments for rare diseases and biodefense. Its future profit projections depend on government contracts and drug approvals. This chart shows analysts' assessments of its development prospects in these specific niches.
%20profit%20of%20the%20company%20Soligenix%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Soligenix-Inc.&v=1772513689508 "Graph of future (projected) profit of the company Soligenix Inc.")
Future (predicted) profit of companies in the market segment - Pharma infections
Soligenix is a biopharmaceutical company developing drugs to treat rare diseases, such as cutaneous T-cell lymphoma, and creating vaccines against bioterrorism threats. This chart shows forecasts for the pharmaceutical segment. It helps assess how a diversified portfolio, including both commercial and government projects, impacts the company's stability.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772513689557 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
For Soligenix, a biopharmaceutical company focused on rare diseases, this schedule is important for access to funding, including government grants. Economic growth allows for increased healthcare and research budgets, while recessions can lead to cuts in these spending.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513689606 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Soligenix Inc.
Soligenix is a biopharmaceutical company focused on rare diseases and biodefense. This chart shows how investors estimate the potential revenue from its developments, including potential government contracts.
P/S market segment - Pharma infections
Soligenix is a late-stage biopharmaceutical company focused on treating rare diseases such as cutaneous T-cell lymphoma and childhood mucositis. This chart shows the average valuation in the infectious diseases and oncology sector. It reflects investor expectations for the potential of the company's drugs in markets with unmet needs.
P/S of the market as a whole
Soligenix, Inc. is a late-stage biopharmaceutical company focused on treating rare diseases such as cutaneous T-cell lymphoma and childhood mucositis. Its valuation depends on rapid approvals. This chart provides an overview of investor sentiment for companies nearing commercialization.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Soligenix Inc.
Soligenix is a biopharmaceutical company focused on treating rare diseases and developing vaccines. Its valuation depends on the success of its late-stage development. The chart shows how investors assess the likelihood of regulatory approval for its drugs and their subsequent commercial potential.
%20P%2FS%20Soligenix%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Soligenix-Inc.&v=1772513689732 "The graph of the company's future (projected) P/S Soligenix Inc.")
Future (projected) P/S of the market segment - Pharma infections
Soligenix is a biopharmaceutical company developing treatments for rare diseases, such as cutaneous T-cell lymphoma, and vaccines against bioterrorism threats, such as ricin. Its portfolio is diversified. This chart shows how the market views the potential of its various development programs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772513689769 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
This indicator reflects the market's faith in biotechnology. For Soligenix, a company developing drugs for rare diseases and biodefense, it's an indicator of capital availability. Market optimism allows for funding the development of vaccines and therapies that could be important for both individual patients and national security.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513689865 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Soligenix Inc.
Soligenix is a biopharmaceutical company developing treatments for rare diseases, such as cutaneous T-cell lymphoma, and vaccines. This chart reflects revenue from government contracts and grants. Future revenue is dependent on the approval and commercialization of its drugs and vaccines.
Sales of companies in the market segment - Pharma infections
Soligenix, Inc. is a biopharmaceutical company developing drugs to treat rare diseases with unmet medical needs. This chart shows the dynamics of the infection control drug sector. Soligenix works in areas such as cutaneous T-cell lymphoma and mucositis, solving complex medical problems.
Overall market sales
Soligenix, Inc. is a biopharmaceutical company focused on rare disease treatments and biodefense. Its growth depends on successful trials and government contracts. This general economic activity schedule influences the amount of government funding for healthcare and biodefense programs, which can be a source of revenue for the company.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Soligenix Inc.
Soligenix is a biopharmaceutical company developing treatments for rare diseases, such as cutaneous T-cell lymphoma, as well as biodefense vaccines. Its portfolio is diversified. This chart reflects aggregate analyst expectations for several of the company's late-stage development programs.
%20sales%20of%20the%20company%20Soligenix%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Soligenix-Inc.&v=1772513690096 "Schedule of future (projected) sales of the company Soligenix Inc.")
Future (projected) sales of companies in the market segment - Pharma infections
Soligenix is a biopharmaceutical company developing treatments for rare diseases such as cutaneous T-cell lymphoma. This chart shows expectations for the infectious diseases and oncology pharmaceutical sectors, providing context for assessing the potential market for Soligenix's niche drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772513690127 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
Soligenix, Inc. is a late-stage biopharmaceutical company focused on rare disease treatments and biodefense. Its portfolio includes orphan disease treatments and vaccines. This graph, reflecting the state of the economy, influences the amount of government funding for biodefense programs, which could be a source of revenue for Soligenix.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513690141 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Soligenix Inc.
Soligenix is a biopharmaceutical company focused on rare diseases and biodefense. This chart shows the company's financial performance with products in late stages of development. Profitability depends on regulatory approval and successful commercialization, which may be supported by government contracts.
Market segment marginality - Pharma infections
Soligenix is a biopharmaceutical company developing treatments for rare diseases such as cutaneous T-cell lymphoma and mucositis. For a company focused on orphan drugs, this chart shows the potential. It reflects the average profitability in its sector, which Soligenix aims to achieve if its drugs are approved and brought to market.
Market marginality as a whole
Soligenix is a late-stage biopharmaceutical company developing drugs for rare diseases and biodefense. This overall market profitability curve is not key for the company. Its success depends on regulatory approvals and government contracts in the biodefense sector, not on overall economic trends.
Employees in the company, segment and market as a whole
Number of employees in the company Soligenix Inc.
Soligenix is a late-stage biopharmaceutical company developing drugs to treat rare diseases such as cutaneous T-cell lymphoma. This graph shows a small team focused on completing clinical trials and submitting regulatory applications.
Share of the company's employees Soligenix Inc. within the market segment - Pharma infections
Soligenix develops treatments for rare diseases, such as cutaneous T-cell lymphoma, as well as biodefense vaccines. This chart shows the proportion of scientists and clinicians working in these specific and critical areas the company attracts. It reflects its diversified scientific capabilities and concentration of niche expertise.
Number of employees in the market segment - Pharma infections
Soligenix is a biopharmaceutical company working on treating rare diseases and developing vaccines against bioterrorism threats. This graph illustrates how public health and national security challenges are driving scientific research, creating a demand for biologists and physicians working to protect the public from various threats.
Number of employees in the market as a whole
Soligenix, Inc. develops treatments for rare diseases for which there is often no effective therapy. This is a socially significant segment of the pharmaceutical industry. This graph illustrates the overall employment picture, and the work of companies like Soligenix demonstrates that the market is capable of solving not only widespread but also highly specialized problems, creating jobs in the process.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Soligenix Inc. (SNGX)
Soligenix is a biotech company specializing in rare diseases and biodefense. This chart represents a pure intellectual capital valuation. The company's value is based on market expectations for its drug candidates (for example, for the treatment of lymphoma). The chart shows the high future value the market attributes to these developments, per scientist.
%20of%20the%20company%20Soligenix%20Inc.%20(SNGX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Soligenix-Inc.-SNGX&v=1772513690331 "Chart of market capitalization per employee (in thousands of dollars) of the company Soligenix Inc. (SNGX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
Soligenix, Inc. develops treatments for rare diseases and biodefense. This is a niche but important sector of the pharmaceutical industry. The chart shows how the market values their expertise and development pipeline per employee. A comparison with the industry reveals the value of their focused business model.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772513690385 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
Soligenix, Inc. is a biopharmaceutical company developing treatments for rare diseases and biodefense. This chart shows the market-wide performance metric per employee, allowing for the evaluation of its diversified development portfolio.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513690426 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Soligenix Inc. (SNGX)
Soligenix is a clinical-stage biotech company with no commercial products. This chart shows the net loss per employee. It reflects not inefficiency, but the company's "bet"—how much it invests in each scientist to conduct research and develop breakthrough therapies.
%20Chart%20Soligenix%20Inc.%20(SNGX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Soligenix-Inc.-SNGX&v=1772513690431 "Company Profit Per Employee (in thousands of dollars) Chart Soligenix Inc. (SNGX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
Soligenix, Inc. is a late-stage biopharmaceutical company focused on treating rare diseases such as cutaneous T-cell lymphoma. Its core business is clinical research. The negative earnings per employee this chart likely shows is typical for biotech companies investing in their scientific teams to bring their products to market.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772513690529 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
Soligenix (SNGX) is a late-stage biopharmaceutical company developing therapies for rare diseases, specifically HyBryte (for cutaneous T-cell lymphoma) and SGX942 (for oral mucositis). This is an R&D business. This chart shows the market average dollar return per employee. For SNGX (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513690621 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Soligenix Inc. (SNGX)
Soligenix is a late-stage biopharmaceutical company focused on rare diseases. This graph shows its proximity to commercialization. Its growth will signify successful product approval and launch, allowing the company to finally convert years of research into stable revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Soligenix-Inc.-SNGX&v=1772513690638 "Sales chart per company employee Soligenix Inc. (SNGX)")
Sales per employee in the market segment - Pharma infections
Soligenix is a late-stage R&D biotech company focused on treating rare diseases and developing vaccines. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Soligenix's staff.
Sales per employee for the market as a whole
Soligenix is a late-stage biotech company focused on treating rare diseases (such as cutaneous T-cell lymphoma) and developing vaccines. The company has no commercial revenue, which is irrelevant. Its value lies in the potential of its R&D team to secure approval for its drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Soligenix Inc. (SNGX)
Soligenix is a biotech company with a very broad pipeline, including treatments for rare skin diseases and vaccine development (including ricin). This chart shows the odds that their developments will fail. "Bears" believe the company will fail to secure FDA approval for any of its many pipelines.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Soligenix-Inc.-SNGX&v=1772513690762 "Short Shares Chart for the Company Soligenix Inc. (SNGX)")
Shares shorted by market segment - Pharma infections
Soligenix, Inc. is a biopharmaceutical company developing treatments for rare diseases, such as cutaneous T-cell lymphoma, and vaccines (including an Ebola vaccine). This chart shows the overall short position in the infectious disease-focused biotech sector. Its rise reflects investor skepticism about the success of clinical trials in these complex areas.
Shares shorted by the overall market
Soligenix is a late-stage biotech targeting rare diseases like cutaneous T-cell lymphoma. This chart illustrates the overall market pessimism. Even late-stage biotechs like SNGX still face binary risk (FDA approval/rejection). When fear reigns in the market, investors are unwilling to accept this risk and prefer to lock in losses.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Soligenix Inc. (SNGX)
Soligenix, Inc. is a late-stage biotech company developing treatments for rare diseases (such as cutaneous T-cell lymphoma) and vaccines for biodefense. This indicator tracks how investors react to binary events—FDA decisions—by showing "overheated" (above 70) in anticipation of approval or "oversold" (below 30) after a rejection.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Soligenix-Inc.-SNGX&v=1772513690892 "RSI 14 indicator chart for the company's stock Soligenix Inc. (SNGX)")
RSI 14 Market Segment - Pharma infections
Soligenix is a biotech company with two segments: rare disease treatment (cutaneous T-cell lymphoma) and vaccine development (including an Ebola vaccine). This chart measures the overall momentum in the biotech sector. It helps separate SNGX volatility from the overall industry trend.
RSI 14 for the overall market
For Soligenix, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SNGX (Soligenix Inc.)
Soligenix is a biotech company developing drugs to treat rare diseases, including cutaneous T-cell lymphoma (CTCL) and mucositis. This chart shows the average 12-month forecast of analysts. It reflects their collective bet on FDA approval and commercial success of their drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SNGX-Soligenix-Inc.&v=1772513691008 "A chart showing analyst consensus forecasts for the expected stock price. SNGX (Soligenix Inc.)")
The difference between the consensus estimate and the actual stock price SNGX (Soligenix Inc.)
Soligenix is a biopharmaceutical company with two focuses: treating rare diseases (cutaneous T-cell lymphoma) and developing vaccines (for ricin). This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in this diversified R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SNGX-Soligenix-Inc.&v=1772513691029 "A chart showing the difference between the consensus forecast and the actual stock price. SNGX (Soligenix Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
Soligenix is a dual-use biotech company. It develops R&D drugs for rare diseases and "biodefense" (vaccines) for the government. This chart reflects analysts' overall expectations for the entire infectious disease pharmaceutical sector. It shows whether experts believe government spending on biodefense will increase.
Analysts' consensus forecast for the overall market share price
Soligenix is a biotech company with two platforms: treatment of rare diseases (such as cutaneous lymphoma) and biodefense (development of ricin vaccines). This chart reflects the overall market "risk appetite." For SNGX, a high-risk company, overall market optimism (risk appetite) is important for raising capital, although their biodefense business also depends on government contracts.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Soligenix Inc.
Soligenix is a two-pronged biotech veteran. They have a biodefense division (Ricin vaccines, for government contracts) and a pharmaceutical division (R&D for rare diseases like cutaneous lymphoma). This chart is a summary indicator of their dual focus. It reflects their (speculative) R&D pipeline and their (uneven) revenue from government R&D contracts.
AKIMA Market Segment Index - Pharma infections
Soligenix (SNGX) is a biopharmaceutical company with a diversified portfolio. They are developing both drugs for rare diseases (cutaneous T-cell lymphoma) and vaccines (ricin, COVID-19). The chart shows the segment average, helping investors assess how this dual approach compares to the industry average.
The AKIM Index for the overall market
Soligenix is a biopharmaceutical company developing treatments for rare diseases (skin cancer) and vaccines against bioterrorism (ricin). This chart, reflecting the market average, provides a macro backdrop. It helps assess how Soligenix, which combines commercial and government-funded programs, compares to overall trends.
